Moderna announces this great advantage over Biontech/Pfizer! The vaccine can do better!

Moderna has just announced this major advantage over the Biontech/Pfizer vaccine! The manufacturer’s Chief Medical Officer recently compared the two COVID vaccines and sees a clear advantage of the Moderna vaccine!

Millions of people around the world have received additional COVID vaccinations to increase their protection against the virus, which is still circulating in countries. However, many health authorities believe that only those most at risk need a booster vaccination, as current vaccines are still effective in preventing severe COVID illness. However, this does not mean that all three vaccines are equal. A Sept. 24 study by the Centers for Disease Control and Prevention (CDC) confirmed that the Moderna vaccine is 93 percent effective in preventing severe infection. And that’s not the only reason Moderna has the upper hand according to new data as now revealed!


Moderna with particularly high protection against…

On November 11, Moderna’s Chief Medical Officer, Dr. Paul Burton, discussed the vaccine’s efficacy with reporters, saying that Moderna offers high protection against severe COVID illness, hospitalizations and deaths, as reported by CNBC. Burton also said that data show Moderna’s vaccine has fewer breakthrough cases than Pfizer’s, and referred to further research by the CDC.

According to the chief medical officer, the agency’s data shows that there were 86 breakthrough cases per 100,000 people who received Moderna’s vaccine in the U.S., compared with 135 breakthrough cases per 100,000 people who received Pfizer’s vaccine.

That doesn’t mean there aren’t concerns. In mid-October, the U.S. Food and Drug Administration (FDA) decided to delay its decision to approve the Moderna two-dose vaccine for children ages 12 to 17 to review reports of rare heart inflammation (myocarditis), the Wall Street Journal reported. Currently, Pfizer is the only vaccine approved for use in children under 18.

No heart muscle inflammation with booster?

According to Burton, reported cases of myocarditis in men younger than 30 were relatively higher after Moderna’s vaccine than Pfizer’s. Burton cited data from France showing that there were 13.3 cases of myocarditis per 100,000 men aged 12 to 29 who were vaccinated with Moderna and 2.7 cases per 100,000 among those who received Pfizer.

The chief medical officer pointed out that the company has not yet observed any cases of myocarditis in people who received the booster vaccine. The booster shot is a lower, half-dose of the Moderna vaccine that could reduce the already rare risk of heart inflammation. Burton said that while scientists are still trying to understand why heart muscle inflammation can occur in young men after vaccination, some have hypothesized that the higher dose of Moderna may play a role. The original vaccine contains 100 micrograms, as opposed to Pfizer’s 30 micrograms.

„I think public health officials are carefully evaluating the data and being appropriately cautious, but you can see that they continue to recommend the use of Moderna’s mRNA-1273 vaccine. We think the benefit-to-risk ratio is extremely positive,“ Burton said during the conference call with reporters, adding that his company will continue to monitor myocarditis cases and that most cases are generally mild and symptoms usually resolve on their own.

Beliebteste Artikel Aktuell: